Research graph
References from Circulating PCSK9 and Risk of Myocardial Infarction. Local targets link to admitted publications; unresolved targets remain external evidence.
Lipid lowering with PCSK9 inhibitors
10.1038/nrcardio.2014.84 · 2014 · External reference
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
10.1002/humu.20882 · 2009 · External reference
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
10.1056/nejmoa1501031 · 2015 · External reference
Update of clinical trials of anti-PCSK9 antibodies
10.1007/s10557-015-6582-9 · 2015 · External reference
Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects
10.1016/j.metabol.2013.01.005 · 2013 · External reference
Plasma proprotein convertase subtilisin/kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults
10.1016/j.hlc.2015.10.017 · 2016 · External reference
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
10.1016/j.atherosclerosis.2010.09.027 · 2010 · External reference
Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels
10.1161/atvbaha.111.240549 · 2012 · External reference
Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
10.1016/j.vph.2014.03.004 · 2014 · External reference
Proprotein convertase subtilisin/kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study
10.1097/md.0000000000002426 · 2015 · External reference
Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors
10.1161/circulationaha.115.018531 · 2016 · External reference
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
10.1093/eurheartj/ehv568 · 2016 · External reference
Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention
10.1161/atvbaha.115.306172 · 2015 · External reference
The Nord-Trøndelag Health Study 1995 -97 (HUNT 2): objectives, contents, methods and participation
2003 · External reference
Insomnia and the risk of acute myocardial infarction: a population study
10.1161/circulationaha.111.025858 · 2011 · External reference
Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction
10.1016/s0735-1097(00)00804-4 · 2000 · External reference
Unresolved reference
2008 · External reference
Multiplicative models in cohort analysis
10.1080/01621459.1983.10477915 · 1983 · External reference
Plasma PCSK9 levels correlate with cholesterol in men but not in women
10.1016/j.bbrc.2007.07.029 · 2007 · External reference
Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies
10.1371/journal.pone.0106294 · 2014 · External reference
Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study
10.1159/000319067 · 2010 · External reference
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis
10.1016/j.jacc.2013.07.056 · 2013 · External reference
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
10.1194/jlr.m008144 · 2010 · External reference
Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001
10.1161/circulationaha.108.817619 · 2009 · External reference
Clinical aspects of PCSK9
10.1016/j.atherosclerosis.2011.04.018 · 2011 · External reference
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans
10.1161/atvbaha.110.214130 · 2010 · External reference
